Clinical trial · Observational
OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study
NCT06270771CI-TRIAL-00091862OURA MDSrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective, single center, single arm phase 2 cohort feasibility study of the OURA ring in adult MDS patients. Patients with MDS will wear the OURA ring and upload biometrics weekly. Quality of life measures will be clinically evaluated and correlated with biometrics. We hypothesize that it will be feasible for MDS patients to wear the OURA ring 70% of the time for 3 months.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| MDS | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
| Myelodysplastic/Myeloproliferative Neoplasms | Myelodysplastic/Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
| RARS-T | Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OURA Ring | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Transfusion Dependent
- description
- Patients who are currently receiving transfusions will be assigned to this cohort
- interventionNames
- Device: OURA Ring
- label
- Transfusion Independent
- description
- Patients who are not currently receiving transfusions will be assigned to this cohort
- interventionNames
- Device: OURA Ring
Primary outcomes (1)
- measure
- Feasibility of patients with MDS wearing the OURA ring
- timeFrame
- 3 months
- description
- Feasibility will be defined as being worn 70% of the time and uploaded to a web-based database weekly x 3 months.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged 18 or older 4. Able to read, write and speak English or French (non-English or French speaking patients may participate if appropriate translation is used) 5. Diagnosed with Myelodysplastic Syndrome using WHO 2022 criteria (12) all risk groups 6. Ability to wear the OURA ring and operate the associated smart-phone app, and willing to adhere to the study regimen Exclusion Criteria: 1. Performance status ECOG \> 3. 2. Cognitive or physical impairment preventing the usage or utilization of the OURA ring and smart phone.
References
Publications (0)
Data not yet available
No reference posted for this study.